Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Change in Inventory (2016 - 2025)

Historic Change in Inventory for Orthofix Medical (OFIX) over the last 15 years, with Q3 2025 value amounting to $3.6 million.

  • Orthofix Medical's Change in Inventory rose 18654.92% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 7363.88%. This contributed to the annual value of $5.5 million for FY2024, which is 9044.63% down from last year.
  • According to the latest figures from Q3 2025, Orthofix Medical's Change in Inventory is $3.6 million, which was up 18654.92% from $6.6 million recorded in Q2 2025.
  • In the past 5 years, Orthofix Medical's Change in Inventory registered a high of $16.8 million during Q1 2023, and its lowest value of -$4.3 million during Q4 2024.
  • For the 5-year period, Orthofix Medical's Change in Inventory averaged around $6.1 million, with its median value being $6.6 million (2025).
  • Its Change in Inventory has fluctuated over the past 5 years, first soared by 5349375.0% in 2022, then crashed by 14322.85% in 2024.
  • Quarter analysis of 5 years shows Orthofix Medical's Change in Inventory stood at $9.3 million in 2021, then tumbled by 66.12% to $3.2 million in 2022, then surged by 212.39% to $9.9 million in 2023, then plummeted by 143.23% to -$4.3 million in 2024, then skyrocketed by 183.74% to $3.6 million in 2025.
  • Its Change in Inventory was $3.6 million in Q3 2025, compared to $6.6 million in Q2 2025 and -$693000.0 in Q1 2025.